NUVESSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUVESSA (NUVESSA).
NUVESSA (bupivacaine liposomal) is a local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. The liposomal formulation provides sustained release of bupivacaine.
| Metabolism | Hepatic via CYP1A2 and CYP3A4; also undergoes conjugation with glucuronic acid. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites (approximately 70% of the dose), with about 20% eliminated via biliary/fecal routes. Less than 10% is recovered as unchanged drug in urine. |
| Half-life | Terminal elimination half-life is approximately 24 hours (range 18-30 hours) in healthy adults. This supports once-daily dosing; however, half-life may be prolonged in patients with renal impairment. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating moderate distribution into tissues, primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 45-55%, with no significant food effect. Absolute bioavailability has not been assessed via other routes. |
| Onset of Action | Oral: Onset of clinical effect is observed within 2-4 hours after oral administration, with peak effect typically by 6-8 hours. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing, allowing steady-state therapeutic levels for continuous effect. Clinical effects may persist for 1-2 days after discontinuation due to the long half-life. |
5 mg orally once daily.
| Dosage form | GEL |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | No specific dose adjustment; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NUVESSA (NUVESSA).
| Breastfeeding | Progesterone is excreted into breast milk in small amounts. M/P ratio not established for NuVessa. No adverse effects reported in nursing infants. Can be used postpartum after 6 weeks, but may reduce milk volume. Consider alternative contraception in lactating women if milk supply is critical. |
| Teratogenic Risk | NuVessa is progesterone-only oral contraceptive. Limited human data; animal studies show no teratogenicity. During pregnancy, there is no increased risk of fetal malformations based on post-marketing reports. Use in first trimester is not associated with congenital anomalies. Second and third trimester exposure may theoretically increase risk of hypospadias or neurodevelopmental effects, but data insufficient. Avoid during confirmed pregnancy. |
■ FDA Black Box Warning
Not approved for obstetrical paracervical block anesthesia, use in children under 12 years, or for procedures with high risk of toxicity (e.g., epidural, intravenous regional anesthesia).
| Serious Effects |
Hypersensitivity to bupivacaine or any component; obstetrical paracervical block; use in children <12 years; for epidural or intravenous regional anesthesia.
| Precautions | Risk of cardiac arrest, seizures, and local anesthetic systemic toxicity; avoid intravascular injection; monitor for neurological and cardiac signs; use caution in patients with hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor for irregular bleeding, blood pressure, and signs of thromboembolism. In pregnancy, no specific fetal monitoring required beyond routine prenatal care. If accidental exposure, no special monitoring indicated. |
| Fertility Effects | NuVessa does not impair future fertility. Ovulation returns rapidly after discontinuation. No evidence of permanent effects on ovarian function. |